Related Experiment Video
Updated: Aug 27, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Activated Platelets, the Booster of Chronic Kidney Disease and Cardiovascular Complications
Shuiqin Gong1, Chenyu Wang1, Jiachuan Xiong1
1Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Insights
Chronic kidney disease (CKD) and its cardiovascular complications pose significant health challenges. Platelets play a key role in both CKD and related cardiovascular diseases, highlighting a potential therapeutic target.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Chronic kidney disease (CKD) is a growing global health concern.
- Cardiovascular diseases (CVDs) are the leading cause of mortality in advanced CKD patients.
- Effective management of CKD-related cardiovascular complications remains a significant clinical challenge.
Purpose of the Study:
- To investigate the role of platelets in the pathophysiology of CKD.
- To explore the involvement of platelets in CKD-associated cardiovascular diseases.
- To identify potential therapeutic strategies targeting platelet function in CKD.
Main Methods:
- Review of current literature on platelet biology and function.
- Analysis of studies investigating platelet activation and aggregation in CKD.
- Examination of research on the link between platelets and cardiovascular complications in CKD patients.
Main Results:
- Platelets are implicated in various physiological and pathological processes relevant to CKD.
- Evidence suggests platelets contribute to the development and progression of CKD-related CVDs.
- Platelet activation and dysfunction are observed in CKD patients.
Conclusions:
- Platelets are critical players in both CKD and its cardiovascular complications.
- Targeting platelet pathways may offer novel therapeutic avenues for managing CKD patients.
- Further research is warranted to fully elucidate platelet mechanisms in CKD-CVD.
Abstract:
Background Chronic kidney disease (CKD) has become a global public health problem nowadays. As cardiovascular diseases (CVDs) are the primary cause of death in advanced CKD patients, much attention has been paid to resolving their cardiovascular complications. However, managing CKD and cardiovascular complications is still a big challenge for nephrologists, as satisfactory treatments are still lacking. Platelets, the second most abundant cells in the blood, are the major participants of hemostasis, thrombosis, and wound healing. In recent years, platelets have been reported in various physiological and pathological processes, including CKD and CKD-related CVDs.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

